Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07946315. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension: A Randomized, Double-Masked, Placebo-Controlled Phase 2 Trial of Adjunctive Tirzepatide
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are: * Does tirzepatide lower the mean daily acetazolamide dose at 12 months? * Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension? Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache. In addition to receiving treatment with acetazolamide, participants will: * Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation. * Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing. * During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment. * Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.
Study identification
- NCT ID
- NCT07946315
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 75 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 1, 2027 (Estimated)
- Primary completion
- May 1, 2030 (Estimated)
- Completion
- May 1, 2030 (Estimated)
- Last update posted
- Nov 18, 2026
2027 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02446 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07946315, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.